© 2022 MJH Life Sciences and Ophthalmology Times. All rights reserved.
© 2022 MJH Life Sciences™ and Ophthalmology Times. All rights reserved.
Retina specialists discuss 2-year data updates in the TENAYA, LUCERNE, YOSEMITE, and RHINE trials for wet macular degeneration (wet AMD) and diabetic macular edema (DME).
August 30th 2022
David A. Eichenbaum, MD, FASRS, and Caroline Baumal, MD, discuss how AMD and DME impact a patient’s quality of life.
Retina specialists discuss which factors impact treatment selection and how to incorporate shared decision-making into treatment selection when treating patients with AMD and DME.
Drs David A. Eichenbaum and Caroline Baumal discuss implications of the treat-and-extend approach with faricimab in patients with wet AMD.
David A. Eichenbaum, MD, FASRS, and Caroline Baumal, MD, review the dual mechanism of action of faricimab as well as the 2-year update in the TENAYA, LUCERNE, YOSEMITE, and RHINE trials.
Retina specialists discuss how to incorporate faricimab into clinical practice and discuss implacations of the TRUCKEE study.
Drs David A. Eichenbaum and Caroline Baumal discuss unmet needs in treating AMD and DME.
David A. Eichenbaum, MD, FASRS and Caroline Baumal, MD provide take-home messages to providers treating AMD and DME.
Orbis in-person training taking flight once again
VIDEO: Eye trauma: Treatment trends and innovations
NYU Langone Health receives awards for quality, safety